Table 1 Baseline clinical characteristics of study patients.

From: Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission

 

Total (n = 75)

Gender, n (%)

 Male

 Female

48 (64.0)

27 (36.0)

Observational period, months

41.5 (23.0, 58.7)

Age at diagnosis, years

14.2 (12.0, 17.0)

Age group, n (%)

 5–9 years

 10–14 years

 15–19 years

5 (6.6)

35 (46.7)

35 (46.7)

Initial BMI at diagnosis, kg/m2

19.0 (16.8, 20.7)

Initial PCDAI at diagnosis

39.7 (37.5, 45.0)

Disease location, n (%)

 Ileal (L1)

 Colonic (L2)

 Ileocolonic (L3)

9 (12.0)

3 (4.0)

61 (81.3)

Upper gastrointestinal involvement, n (%)

 None

 Proximal to the ligament of Treitz (L4a)

 Distal to the ligament of Treitz and proximal to the distal 1/3 ileum (L4b)

 Both (L4ab)

1 (1.3)

9 (12.0)

9 (12.0)

56 (74.7)

Behavior of disease, n (%)

 Inflammatory (B1)

 Stricturing (B2)

 Penetrating (B3)

52 (69.3)

20 (26.7)

3 (4.0)

Growth delay, n (%)

 No evidence of growth delay (G0)

 Growth delay (G1)

51 (68.0)

24 (32.0)

Perianal disease, n (%)

43 (57.3)

Initial Laboratory findings

 White blood cell count, × 103/μL

 Hematocrit, %

 Platelet count, × 103/μL

 Erythrocyte sedimentation rate, mm/h

 C-reactive protein, mg/dL

 Albumin, g/dL

8.8 (6.7, 11.1)

36.8 (33.4, 39.8)

382 (309, 491)

55.0 (29.5, 77.5)

3.1 (0.8, 4.3)

3.8 (3.4, 4.3)

Initial SES-CD at diagnosis

16.9 (11.0, 24.0)

Concomitant medication, n (%)

 Mesalazine

73 (97.3)

  1. Baseline characteristics of subjects were explored with descriptive statistics through frequencies (proportion) for categorical variables or medians (interquartile range[IQR]) for continuous variables.
  2. BMI, body mass index; PCDAI, pediatric Crohn’s disease activity index; SES-CD, simple endoscopic score for Crohn’s disease; 6-TGN, 6-thioguanine nucleotide.
Back to article page